The Medical Letter on Drugs and Therapeutics
Pregabalin (Lyrica) for Neuropathic Pain and Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Pregabalin (Lyrica – Pfizer), a structural analog of gamma-aminobutyric acid (GABA) similar to gabapentin (Neurontin – Pfizer, and others), which recently became available generically, has been approved by the FDA for treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN), and for adjunctive treatment of partial onset seizures in adults with epilepsy.

NEUROPATHIC PAIN — Standard Treatment – Drugs used to treat neuropathic pain have included tricyclic antidepressants, antiepileptics, opioid analgesics and topical preparations (capsaicin and lidocaine). Gabapentin, which is FDA-approved for treatment of PHN, is probably the most widely used. Duloxetine (Cymbalta) was recently approved for treatment of DPN.1

Clinical Studies – In clinical studies summarized in the table, treatment ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pregabalin (Lyrica) for Neuropathic Pain and Epilepsy
Article code: 1217b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian